Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin plus empagliflozin versus metformin in women with polycystic ovary syndrome
IRCT20231207060284N1Phase 2Completed
- Sponsor
- Semnan University of Medical Sciences
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of metformin and empagliflozin in polycystic ovary syndrome (PCOS) (2 arms), sponsored by Semnan University of Medical Sciences. Primary endpoints: Insulin resistance, Luteinizing hormone and 4 more. Started Apr 2024; status: completed.
02
Drugs
metforminempagliflozin
03
Conditions
polycystic ovary syndrome (PCOS)
Beyond the preview
Go deeper on IRCT20231207060284N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20231207060284N1.